Why Are Hospitals Spending So Much On Ineffective C-19 Treatments?

Why are hospitals pushing Remdesivir? "...our drug approval system is broken." - Dr. Pierre Kory

Resource Link for Why Are Hospitals Spending So Much On Ineffective C-19 Treatments? (opens new window)

Article on RealClear Markets by Dr. Pierre Kory.

From the article:

Despite some initial indication that Remdesivir might slightly reduce recovery time, the World Health Organization conducted a large-scale analysis that found it “had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.” Unsurprisingly, the WHO recommended against using this drug to treat Covid-19 in November 2020 (and still does).

And one more:

How is it possible that an ineffective and potentially dangerous drug that is scarcely used throughout the world received more money from U.S. hospitals than any other drug?

The answer is because our drug approval system is broken. It’s skewed towards expensive, patented, often marginally beneficial or unknowingly dangerous treatments produced by our pharmaceutical industry to the detriment of well-known, safe, cheap, generic drugs – and ultimately patients.

It’s a good article

Resource Category: COVID

As censorship increases also consider using email and text messages to send links.

Leave a Reply

Your email address will not be published. Required fields are marked *